{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T19:43:26Z","timestamp":1791315806191,"version":"4.3.1"},"reference-count":97,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100008322","name":"CSL Behring","doi-asserted-by":"publisher","award":["074-02-2018-330"],"award-info":[{"award-number":["074-02-2018-330"]}],"id":[{"id":"10.13039\/100008322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007343","name":"Shire","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007343","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaci-inpractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1016\/j.jaip.2019.02.013","type":"journal-article","created":{"date-parts":[[2019,2,23]],"date-time":"2019-02-23T13:19:31Z","timestamp":1550927971000},"page":"1929-1957.e5","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":61,"title":["Health-Related Quality of Life in Children and Adults with Primary Immunodeficiencies: A Systematic Review and Meta-Analysis"],"prefix":"10.1016","volume":"7","author":[{"given":"Dmitrii","family":"Peshko","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekaterina","family":"Kulbachinskaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilya","family":"Korsunskiy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Kondrikova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Pulvirenti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabella","family":"Quinti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oleg","family":"Blyuss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey","family":"Dunn Galvin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Munblit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaip.2019.02.013_bib1","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1007\/s10875-015-0198-5","article-title":"The 2015 IUIS Phenotypic Classification for Primary Immunodeficiencies","volume":"35","author":"Bousfiha","year":"2015","journal-title":"J\u00a0Clin Immunol"},{"key":"10.1016\/j.jaip.2019.02.013_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10875-012-9751-7","article-title":"Primary immunodeficiency diseases worldwide: more common than generally thought","volume":"33","author":"Bousfiha","year":"2013","journal-title":"J\u00a0Clin Immunol"},{"key":"10.1016\/j.jaip.2019.02.013_bib3","doi-asserted-by":"crossref","first-page":"665","DOI":"10.3389\/fimmu.2017.00665","article-title":"Recurrent and sustained viral infections in primary immunodeficiencies","volume":"8","author":"Ruffner","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaip.2019.02.013_bib4","doi-asserted-by":"crossref","first-page":"603","DOI":"10.3349\/ymj.2012.53.3.603","article-title":"Health related quality of life in common variable immunodeficiency","volume":"53","author":"Quinti","year":"2012","journal-title":"Yonsei Med J"},{"key":"10.1016\/j.jaip.2019.02.013_bib5","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1007\/s10875-016-0279-0","article-title":"Health-related quality of life and health resource utilization in patients with primary immunodeficiency disease prior to and following 12 months of immunoglobulin G treatment","volume":"36","author":"Routes","year":"2016","journal-title":"J\u00a0Clin Immunol"},{"key":"10.1016\/j.jaip.2019.02.013_bib6","first-page":"30","article-title":"Physical health conditions and quality of life in adults with primary immunodeficiency diagnosed during childhood: a French Reference Center for PIDs (CEREDIH) study","volume":"30","author":"Barlogis","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2019.02.013_bib7","first-page":"23","article-title":"Health-related quality of life in primary immune deficient patients","volume":"5","author":"Mozaffari","year":"2006","journal-title":"Iran"},{"key":"10.1016\/j.jaip.2019.02.013_bib8","first-page":"605","article-title":"Longitudinal study on health-related quality of life in a cohort of 96 patients with common variable immune deficiencies","volume":"5","author":"Tabolli","year":"2014","journal-title":"Front"},{"key":"10.1016\/j.jaip.2019.02.013_bib9","doi-asserted-by":"crossref","first-page":"323","DOI":"10.2147\/PPA.S58040","article-title":"Health-related quality of life, anxiety, and depressive symptoms in children with primary immunodeficiencies","volume":"8","author":"Kuburovic","year":"2014","journal-title":"Patient Prefer Adherence"},{"key":"10.1016\/j.jaip.2019.02.013_bib10","doi-asserted-by":"crossref","first-page":"27","DOI":"10.14785\/lpsn-2014-0001","article-title":"Home gammaglobulin therapy: a patient survey of intravenous and subcutaneous options in Canada","volume":"1","author":"Reid","year":"2014","journal-title":"LymphoSign J"},{"key":"10.1016\/j.jaip.2019.02.013_bib11","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/j.jpeds.2008.12.020","article-title":"Common variable immunodeficiency disorders in children: delayed diagnosis despite typical clinical presentation","volume":"154","author":"Urschel","year":"2009","journal-title":"J\u00a0Pediatr"},{"key":"10.1016\/j.jaip.2019.02.013_bib12","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/1741-7015-9-86","article-title":"Measuring patient-reported outcomes: moving beyond misplaced common sense to hard science","volume":"9","author":"McKenna","year":"2011","journal-title":"BMC Med"},{"key":"10.1016\/j.jaip.2019.02.013_bib13","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s13223-015-0092-y","article-title":"Health-related quality of life in patients with primary immunodeficiency disease","volume":"11","author":"Jiang","year":"2015","journal-title":"Allergy Asthma Clin Immunol"},{"key":"10.1016\/j.jaip.2019.02.013_bib14","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s12955-016-0483-x","article-title":"Standardizing disease-specific quality of life measures across multiple chronic conditions: development and initial evaluation of the QOL Disease Impact Scale (QDIS(R))","volume":"14","author":"Ware","year":"2016","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.jaip.2019.02.013_bib15","doi-asserted-by":"crossref","first-page":"b2535","DOI":"10.1136\/bmj.b2535","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"339","author":"Moher","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.jaip.2019.02.013_bib16","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1002\/bdra.23030","article-title":"A\u00a0systematic review of studies of quality of life in children and adults with selected congenital anomalies","volume":"94","author":"Glinianaia","year":"2012","journal-title":"Birth Defects Res A Clin Mol Teratol"},{"key":"10.1016\/j.jaip.2019.02.013_bib17","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1471-2431-9-6","article-title":"Psychological adjustment and quality of life in children and adolescents following open-heart surgery for congenital heart disease: a systematic review","volume":"9","author":"Latal","year":"2009","journal-title":"BMC Pediatr"},{"key":"10.1016\/j.jaip.2019.02.013_bib18","doi-asserted-by":"crossref","first-page":"e1129","DOI":"10.1542\/peds.2014-0352","article-title":"Self-reported quality of life of young children with conditions from early infancy: a systematic review","volume":"134","author":"Jardine","year":"2014","journal-title":"Pediatrics"},{"key":"10.1016\/j.jaip.2019.02.013_bib20","series-title":"Introduction to Meta-Analysis","author":"Borenstein","year":"2009"},{"key":"10.1016\/j.jaip.2019.02.013_bib21","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1016\/j.jaip.2016.07.012","article-title":"Development and initial validation of a questionnaire to measure health-related quality of life of adults with common variable immune deficiency: the CVID_QoL Questionnaire","volume":"4","author":"Quinti","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2019.02.013_bib22","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s13023-016-0452-9","article-title":"Does the route of immunoglobin replacement therapy impact quality of life and satisfaction in patients with primary immunodeficiency? Insights from the French cohort \u201cVisages\u201d","volume":"11","author":"Bienvenu","year":"2016","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.jaip.2019.02.013_bib23","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1007\/s11136-013-0491-9","article-title":"Health-related quality of life (HRQL) in immunodeficient adults with selective IgA deficiency compared with age- and gender-matched controls and identification of risk factors for poor HRQL","volume":"23","author":"Jorgensen","year":"2014","journal-title":"Qual Life Res"},{"key":"10.1016\/j.jaip.2019.02.013_bib24","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/j.1759-8893.2011.00076.x","article-title":"Patients with primary immunodeficiency receiving subcutaneous immune globulin Hizentra maintain health-related quality of life and treatment satisfaction in a multicentre extension study of efficacy, tolerability and safety","volume":"3","author":"Jones","year":"2012","journal-title":"J\u00a0Pharmaceut Health Serv Res"},{"key":"10.1016\/j.jaip.2019.02.013_bib25","first-page":"47","article-title":"Health-related quality of life in primary antibody deficiency","volume":"10","author":"Aghamohammadi","year":"2011","journal-title":"Iran"},{"key":"10.1016\/j.jaip.2019.02.013_bib26","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1097\/MD.0b013e318187ed81","article-title":"Adults with X-linked agammaglobulinemia: impact of disease on daily lives, quality of life, educational and socioeconomic status, knowledge of inheritance, and reproductive attitudes","volume":"87","author":"Winkelstein","year":"2008","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.jaip.2019.02.013_bib27","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.clim.2005.11.002","article-title":"The health status and quality of life of adults with X-linked agammaglobulinemia","volume":"118","author":"Howard","year":"2006","journal-title":"Clin Immunol"},{"key":"10.1016\/j.jaip.2019.02.013_bib28","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/1477-7525-3-31","article-title":"Coping, quality of life, and hope in adults with primary antibody deficiencies","volume":"3","author":"Sigstad","year":"2005","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.jaip.2019.02.013_bib29","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/S1081-1206(10)61469-X","article-title":"Quality of life in common variable immunodeficiency requiring intravenous immunoglobulin therapy","volume":"93","author":"Tcheurekdjian","year":"2004","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2019.02.013_bib30","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1007\/s10875-014-0072-x","article-title":"Quality of life in children with primary antibody deficiency","volume":"34","author":"Titman","year":"2014","journal-title":"J\u00a0Clin Immunol"},{"key":"10.1016\/j.jaip.2019.02.013_bib31","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s10875-008-9270-8","article-title":"The quality of life of children and adolescents with X-linked agammaglobulinemia","volume":"29","author":"Soresina","year":"2009","journal-title":"J\u00a0Clin Immunol"},{"key":"10.1016\/j.jaip.2019.02.013_bib32","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/S1081-1206(10)61263-X","article-title":"Health-related quality of life of children with primary immunodeficiency disease: a comparison study","volume":"93","author":"Zebracki","year":"2004","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2019.02.013_bib33","first-page":"400","article-title":"Clinical profile, dosing, and quality-of-life outcomes in primary immune deficiency patients treated at home with immunoglobulin G: data from the IDEaL Patient Registry","volume":"23","author":"Kearns","year":"2017","journal-title":"J\u00a0Manag Care Spec Pharm"},{"key":"10.1016\/j.jaip.2019.02.013_bib34","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1080\/08820139.2016.1258710","article-title":"Measurement of health-related quality of life in primary antibody-deficient patients","volume":"46","author":"Ataeinia","year":"2017","journal-title":"Immunol Investig"},{"key":"10.1016\/j.jaip.2019.02.013_bib35","doi-asserted-by":"crossref","first-page":"621","DOI":"10.2147\/PPA.S60771","article-title":"Improving current immunoglobulin therapy for patients with primary immunodeficiency: quality of life and views on treatment","volume":"8","author":"Espanol","year":"2014","journal-title":"Patient Prefer Adherence"},{"key":"10.1016\/j.jaip.2019.02.013_bib36","first-page":"289","article-title":"Immunoglobulins for primary or secondary immunodeficiency or for immunomodulation in neurological autoimmune diseases: insights from the prospective SIGNS registry","volume":"20","author":"Kirch","year":"2012","journal-title":"J\u00a0Public Health (Germany)"},{"key":"10.1016\/j.jaip.2019.02.013_bib37","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/s10875-012-9758-0","article-title":"Health related quality of life and emotional health in children with chronic granulomatous disease: a comparison of those managed conservatively with those that have undergone haematopoietic stem cell transplant","volume":"33","author":"Cole","year":"2013","journal-title":"J\u00a0Clin Immunol"},{"key":"10.1016\/j.jaip.2019.02.013_bib38","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s40261-015-0270-1","article-title":"Subcutaneous immunoglobulin replacement therapy in patients with primary immunodeficiency in routine clinical practice: the VISPO prospective multicenter study","volume":"35","author":"Vultaggio","year":"2015","journal-title":"Clin Drug Invest"},{"key":"10.1016\/j.jaip.2019.02.013_bib39","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/cei.12623","article-title":"Efficacy and tolerability of 16% subcutaneous immunoglobulin compared with 20% subcutaneous immunoglobulin in primary antibody deficiency","volume":"181","author":"Niebur","year":"2015","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.jaip.2019.02.013_bib40","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1097\/SMJ.0b013e3181eba6ea","article-title":"Improved quality of life, immunoglobulin G levels, and infection rates in patients with primary immunodeficiency diseases during self-treatment with subcutaneous immunoglobulin G","volume":"103","author":"Berger","year":"2010","journal-title":"South Med J"},{"key":"10.1016\/j.jaip.2019.02.013_bib41","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.clim.2007.06.009","article-title":"Prognostic factors for health-related quality of life in adults and children with primary antibody deficiencies receiving SCIG home therapy","volume":"126","author":"Gardulf","year":"2008","journal-title":"Clin Immunol"},{"key":"10.1016\/j.jaip.2019.02.013_bib42","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1007\/s11136-005-1746-x","article-title":"Measuring treatment satisfaction in patients with primary immunodeficiency diseases receiving lifelong immunoglobulin replacement therapy","volume":"14","author":"Nicolay","year":"2005","journal-title":"Qual Life Res"},{"key":"10.1016\/j.jaip.2019.02.013_bib43","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/j.jaci.2004.06.053","article-title":"Children and adults with primary antibody deficiencies gain quality of life by subcutaneous IgG self-infusions at home","volume":"114","author":"Gardulf","year":"2004","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2019.02.013_bib44","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.intimp.2016.12.030","article-title":"Rapid infusions of human normal immunoglobulin 50 g\/l are safe and well tolerated in immunodeficiencies and immune thrombocytopenia","volume":"44","author":"Spadaro","year":"2017","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.jaip.2019.02.013_bib45","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1159\/000199723","article-title":"Efficacy of intravenous gammaglobulin for immunoglobulin G subclass and\/or antibody deficiency in adults","volume":"149","author":"Abdou","year":"2009","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.jaip.2019.02.013_bib46","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s10875-006-8905-x","article-title":"Health-related quality of life and treatment satisfaction in North American patients with primary immunedeficiency diseases receiving subcutaneous IgG self-infusions at home","volume":"26","author":"Nicolay","year":"2006","journal-title":"J\u00a0Clin Immunol"},{"key":"10.1016\/j.jaip.2019.02.013_bib47","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1111\/j.1365-2249.1993.tb03380.x","article-title":"The life situations of patients with primary antibody deficiency untreated or treated with subcutaneous gammaglobulin infusions","volume":"92","author":"Gardulf","year":"1993","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.jaip.2019.02.013_bib48","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1002\/ppul.22828","article-title":"Effects of inspiratory muscle training on lung volumes, respiratory muscle strength, and quality of life in patients with ataxia telangiectasia","volume":"49","author":"Felix","year":"2014","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.jaip.2019.02.013_bib49","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1007\/s10875-008-9180-9","article-title":"Quality of life and health-care resource utilization among children with primary immunodeficiency receiving home treatment with subcutaneous human immunoglobulin","volume":"28","author":"Fasth","year":"2008","journal-title":"J\u00a0Clin Immunol"},{"key":"10.1016\/j.jaip.2019.02.013_bib50","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1111\/j.1651-2227.2007.00485.x","article-title":"Safety and efficacy of subcutaneous human immunoglobulin in children with primary immunodeficiency","volume":"96","author":"Fasth","year":"2007","journal-title":"Acta Paediatr"},{"key":"10.1016\/j.jaip.2019.02.013_bib51","doi-asserted-by":"crossref","first-page":"S525","DOI":"10.1016\/j.jaci.2006.01.015","article-title":"Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology","volume":"117","author":"Orange","year":"2006","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2019.02.013_bib52","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1182\/blood-2011-09-377945","article-title":"Morbidity and mortality in common variable immune deficiency over 4 decades","volume":"119","author":"Resnick","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jaip.2019.02.013_bib53","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1007\/s11136-011-9986-4","article-title":"Comparing longitudinal assessments of quality of life by patient and parent in newly diagnosed children with cancer: the value of both raters\u2019 perspectives","volume":"21","author":"Parsons","year":"2012","journal-title":"Qual Life Res"},{"key":"10.1016\/j.jaip.2019.02.013_bib54","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1007\/s11136-013-0428-3","article-title":"The European KIDSCREEN approach to measure quality of life and well-being in children: development, current application, and future advances","volume":"23","author":"Ravens-Sieberer","year":"2014","journal-title":"Qual Life Res"},{"key":"10.1016\/j.jaip.2019.02.013_bib55","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1080\/02673843.2017.1297242","article-title":"Child\u2013parent agreement on health-related quality of life in children with newly diagnosed chronic health conditions: a longitudinal study","volume":"23","author":"Qadeer","year":"2018","journal-title":"Int J Adolesc Youth"},{"key":"10.1016\/j.jaip.2019.02.013_bib56","series-title":"Committee for Medicinal Products for Human Use (CMHP). Reflection paper on the regulatory guidance for the use of health-related quality of life (HRQL) measures in the evaluation of medicinal products","year":"2005"},{"key":"10.1016\/j.jaip.2019.02.013_bib57","series-title":"Guidance for industry: patient-reported outcome measures. Use in medical product development to support labeling claims","year":"2009"},{"key":"10.1016\/j.jaip.2019.02.013_bib58","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1016\/j.jaci.2016.11.029","article-title":"Construction and validation of a novel disease-specific quality-of-life instrument for patients with primary antibody deficiency disease (PADQOL-16)","volume":"139","author":"Ballow","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2019.02.013_bib59","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1007\/s10875-012-9720-1","article-title":"Home-based subcutaneous immunoglobulin versus hospital-based intravenous immunoglobulin in treatment of primary antibody deficiencies: systematic review and meta analysis","volume":"32","author":"Abolhassani","year":"2012","journal-title":"J\u00a0Clin Immunol"},{"key":"10.1016\/j.jaip.2019.02.013_bib60","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1007\/s40265-013-0094-3","article-title":"Subcutaneous immunoglobulin for primary and secondary immunodeficiencies: an evidence-based review","volume":"73","author":"Lingman-Framme","year":"2013","journal-title":"Drugs"},{"key":"10.1016\/j.jaip.2019.02.013_bib61","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s12016-018-8700-5","article-title":"Psychosocial mediators of change and patient selection factors in oral immunotherapy trials","volume":"55","author":"DunnGalvin","year":"2018","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.jaip.2019.02.013_bib69","first-page":"30","article-title":"Physical health conditions and quality of life in adults with primary immunodeficiency diagnosed during childhood: a French Reference Center for PIDs (CEREDIH) study","volume":"30","author":"Barlogis","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2019.02.013_bib70","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s13023-016-0452-9","article-title":"Does the route of immunoglobin replacement therapy impact quality of life and satisfaction in patients with primary immunodeficiency? Insights from the French cohort \u201cVisages\u201d","volume":"11","author":"Bienvenu","year":"2016","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.jaip.2019.02.013_bib71","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1016\/j.jaip.2016.07.012","article-title":"Development and initial validation of a questionnaire to measure health-related quality of life of adults with common variable immune deficiency: the CVID_QoL Questionnaire","volume":"4","author":"Quinti","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2019.02.013_bib72","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1007\/s11136-013-0491-9","article-title":"Health-related quality of life (HRQL) in immunodeficient adults with selective IgA deficiency compared with age- and gender-matched controls and identification of risk factors for poor HRQL","volume":"23","author":"Jorgensen","year":"2014","journal-title":"Qual Life Res"},{"key":"10.1016\/j.jaip.2019.02.013_bib73","first-page":"605","article-title":"Longitudinal study on health-related quality of life in a cohort of 96 patients with common variable immune deficiencies","volume":"5","author":"Tabolli","year":"2014","journal-title":"Front"},{"key":"10.1016\/j.jaip.2019.02.013_bib74","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/j.1759-8893.2011.00076.x","article-title":"Patients with primary immunodeficiency receiving subcutaneous immune globulin Hizentra maintain health-related quality of life and treatment satisfaction in a multicentre extension study of efficacy, tolerability and safety","volume":"3","author":"Jones","year":"2012","journal-title":"J\u00a0Pharmaceut Health Serv Res"},{"key":"10.1016\/j.jaip.2019.02.013_bib75","doi-asserted-by":"crossref","first-page":"603","DOI":"10.3349\/ymj.2012.53.3.603","article-title":"Health related quality of life in common variable immunodeficiency","volume":"53","author":"Quinti","year":"2012","journal-title":"Yonsei Med J"},{"key":"10.1016\/j.jaip.2019.02.013_bib76","first-page":"47","article-title":"Health-related quality of life in primary antibody deficiency","volume":"10","author":"Aghamohammadi","year":"2011","journal-title":"Iran"},{"key":"10.1016\/j.jaip.2019.02.013_bib77","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1097\/MD.0b013e318187ed81","article-title":"Adults with X-linked agammaglobulinemia: impact of disease on daily lives, quality of life, educational and socioeconomic status, knowledge of inheritance, and reproductive attitudes","volume":"87","author":"Winkelstein","year":"2008","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.jaip.2019.02.013_bib78","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.clim.2005.11.002","article-title":"The health status and quality of life of adults with X-linked agammaglobulinemia","volume":"118","author":"Howard","year":"2006","journal-title":"Clin Immunol"},{"key":"10.1016\/j.jaip.2019.02.013_bib79","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/1477-7525-3-31","article-title":"Coping, quality of life, and hope in adults with primary antibody deficiencies","volume":"3","author":"Sigstad","year":"2005","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.jaip.2019.02.013_bib80","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/S1081-1206(10)61469-X","article-title":"Quality of life in common variable immunodeficiency requiring intravenous immunoglobulin therapy","volume":"93","author":"Tcheurekdjian","year":"2004","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2019.02.013_bib81","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1080\/08820139.2016.1258710","article-title":"Measurement of health-related quality of life in primary antibody-deficient patients","volume":"46","author":"Ataeinia","year":"2017","journal-title":"Immunol Investig"},{"key":"10.1016\/j.jaip.2019.02.013_bib82","first-page":"400","article-title":"Clinical profile, dosing, and quality-of-life outcomes in primary immune deficiency patients treated at home with immunoglobulin G: data from the IDEaL Patient Registry","volume":"23","author":"Kearns","year":"2017","journal-title":"J\u00a0Manag Care Spec Pharm"},{"key":"10.1016\/j.jaip.2019.02.013_bib83","doi-asserted-by":"crossref","first-page":"621","DOI":"10.2147\/PPA.S60771","article-title":"Improving current immunoglobulin therapy for patients with primary immunodeficiency: quality of life and views on treatment","volume":"8","author":"Espanol","year":"2014","journal-title":"Patient Prefer Adherence"},{"key":"10.1016\/j.jaip.2019.02.013_bib84","doi-asserted-by":"crossref","first-page":"27","DOI":"10.14785\/lpsn-2014-0001","article-title":"Home gammaglobulin therapy: a patient survey of intravenous and subcutaneous options in Canada","volume":"1","author":"Reid","year":"2014","journal-title":"LymphoSign J"},{"key":"10.1016\/j.jaip.2019.02.013_bib85","first-page":"289","article-title":"Immunoglobulins for primary or secondary immunodeficiency or for immunomodulation in neurological autoimmune diseases: insights from the prospective SIGNS registry","volume":"20","author":"Kirch","year":"2012","journal-title":"J\u00a0Public Health (Germany)"},{"key":"10.1016\/j.jaip.2019.02.013_bib86","doi-asserted-by":"crossref","first-page":"323","DOI":"10.2147\/PPA.S58040","article-title":"Health-related quality of life, anxiety, and depressive symptoms in children with primary immunodeficiencies","volume":"8","author":"Kuburovic","year":"2014","journal-title":"Patient Prefer Adherence"},{"key":"10.1016\/j.jaip.2019.02.013_bib87","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1007\/s10875-014-0072-x","article-title":"Quality of life in children with primary antibody deficiency","volume":"34","author":"Titman","year":"2014","journal-title":"J\u00a0Clin Immunol"},{"key":"10.1016\/j.jaip.2019.02.013_bib88","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s10875-008-9270-8","article-title":"The quality of life of children and adolescents with X-linked agammaglobulinemia","volume":"29","author":"Soresina","year":"2009","journal-title":"J\u00a0Clin Immunol"},{"key":"10.1016\/j.jaip.2019.02.013_bib89","first-page":"23","article-title":"Health-related quality of life in primary immune deficient patients","volume":"5","author":"Mozaffari","year":"2006","journal-title":"Iran"},{"key":"10.1016\/j.jaip.2019.02.013_bib90","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/S1081-1206(10)61263-X","article-title":"Health-related quality of life of children with primary immunodeficiency disease: a comparison study","volume":"93","author":"Zebracki","year":"2004","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2019.02.013_bib91","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.intimp.2016.12.030","article-title":"Rapid infusions of human normal immunoglobulin 50 g\/l are safe and well tolerated in immunodeficiencies and immune thrombocytopenia","volume":"44","author":"Spadaro","year":"2017","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.jaip.2019.02.013_bib92","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1159\/000199723","article-title":"Efficacy of intravenous gammaglobulin for immunoglobulin G subclass and\/or antibody deficiency in adults","volume":"149","author":"Abdou","year":"2009","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.jaip.2019.02.013_bib93","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s10875-006-8905-x","article-title":"Health-related quality of life and treatment satisfaction in North American patients with primary immunedeficiency diseases receiving subcutaneous IgG self-infusions at home","volume":"26","author":"Nicolay","year":"2006","journal-title":"J\u00a0Clin Immunol"},{"key":"10.1016\/j.jaip.2019.02.013_bib94","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1111\/j.1365-2249.1993.tb03380.x","article-title":"The life situations of patients with primary antibody deficiency untreated or treated with subcutaneous gammaglobulin infusions","volume":"92","author":"Gardulf","year":"1993","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.jaip.2019.02.013_bib95","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1002\/ppul.22828","article-title":"Effects of inspiratory muscle training on lung volumes, respiratory muscle strength, and quality of life in patients with ataxia telangiectasia","volume":"49","author":"Felix","year":"2014","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.jaip.2019.02.013_bib96","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/s10875-012-9758-0","article-title":"Health related quality of life and emotional health in children with chronic granulomatous disease: a comparison of those managed conservatively with those that have undergone haematopoietic stem cell transplant","volume":"33","author":"Cole","year":"2013","journal-title":"J\u00a0Clin Immunol"},{"key":"10.1016\/j.jaip.2019.02.013_bib97","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1007\/s10875-008-9180-9","article-title":"Quality of life and health-care resource utilization among children with primary immunodeficiency receiving home treatment with subcutaneous human immunoglobulin","volume":"28","author":"Fasth","year":"2008","journal-title":"J\u00a0Clin Immunol"},{"key":"10.1016\/j.jaip.2019.02.013_bib98","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1111\/j.1651-2227.2007.00485.x","article-title":"Safety and efficacy of subcutaneous human immunoglobulin in children with primary immunodeficiency","volume":"96","author":"Fasth","year":"2007","journal-title":"Acta Paediatr"},{"key":"10.1016\/j.jaip.2019.02.013_bib99","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1007\/s10875-016-0279-0","article-title":"Health-related quality of life and health resource utilization in patients with primary immunodeficiency disease prior to and following 12 months of immunoglobulin G treatment","volume":"36","author":"Routes","year":"2016","journal-title":"J\u00a0Clin Immunol"},{"key":"10.1016\/j.jaip.2019.02.013_bib100","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/cei.12623","article-title":"Efficacy and tolerability of 16% subcutaneous immunoglobulin compared with 20% subcutaneous immunoglobulin in primary antibody deficiency","volume":"181","author":"Niebur","year":"2015","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.jaip.2019.02.013_bib101","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s40261-015-0270-1","article-title":"Subcutaneous immunoglobulin replacement therapy in patients with primary immunodeficiency in routine clinical practice: the VISPO prospective multicenter study","volume":"35","author":"Vultaggio","year":"2015","journal-title":"Clin Drug Invest"},{"key":"10.1016\/j.jaip.2019.02.013_bib102","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1097\/SMJ.0b013e3181eba6ea","article-title":"VIRTUE Trial Investigators. Improved quality of life, immunoglobulin G levels, and infection rates in patients with primary immunodeficiency diseases during self-treatment with subcutaneous immunoglobulin G","volume":"103","author":"Berger","year":"2010","journal-title":"South Med J"},{"key":"10.1016\/j.jaip.2019.02.013_bib103","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.clim.2007.06.009","article-title":"Prognostic factors for health-related quality of life in adults and children with primary antibody deficiencies receiving SCIG home therapy","volume":"126","author":"Gardulf","year":"2008","journal-title":"Clin Immunol"},{"key":"10.1016\/j.jaip.2019.02.013_bib104","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1007\/s11136-005-1746-x","article-title":"Measuring treatment satisfaction in patients with primary immunodeficiency diseases receiving lifelong immunoglobulin replacement therapy","volume":"14","author":"Nicolay","year":"2005","journal-title":"Qual Life Res"},{"key":"10.1016\/j.jaip.2019.02.013_bib105","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/j.jaci.2004.06.053","article-title":"Children and adults with primary antibody deficiencies gain quality of life by subcutaneous IgG self-infusions at home","volume":"114","author":"Gardulf","year":"2004","journal-title":"J\u00a0Allergy Clin Immunol"}],"container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219819301795?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219819301795?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T05:18:33Z","timestamp":1761974313000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213219819301795"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":97,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["S2213219819301795"],"URL":"https:\/\/doi.org\/10.1016\/j.jaip.2019.02.013","relation":{},"ISSN":["2213-2198"],"issn-type":[{"value":"2213-2198","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Health-Related Quality of Life in Children and Adults with Primary Immunodeficiencies: A Systematic Review and Meta-Analysis","name":"articletitle","label":"Article Title"},{"value":"The Journal of Allergy and Clinical Immunology: In Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaip.2019.02.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 American Academy of Allergy, Asthma & Immunology","name":"copyright","label":"Copyright"}]}}